In our study, which consisted of a high number of newly diagnosed prostate cancers, we wanted to look at the relationship between D’Amico risk classification, which is the most effective classification system used by clinicians in staging and treatment decision making, and 68Ga-PSMA PET/CT data. This evidence concerns the gene FOLH1 and prostate cancer.